Core Viewpoint - Hutchison China MediTech Limited (和黄医药) is set to present updated data on its self-developed compounds at two major conferences in September 2025, highlighting its ongoing research in lung cancer treatment [1] Group 1: Upcoming Conferences - The company will present at the 2025 World Conference on Lung Cancer (WCLC) in Barcelona, Spain from September 6 to 9 [1] - The company will also present at the 2025 Annual Meeting of the Chinese Society of Clinical Oncology (CSCO) in Jinan, China from September 10 to 14 [1] Group 2: Research Focus - The latest analysis results of the SACHI study, SAVANNAH study, and a Phase IIIb confirmatory study of Savolitinib (赛沃替尼) for non-small cell lung cancer will be disclosed at the WCLC [1] - Savolitinib is described as a potent and highly selective oral MET tyrosine kinase inhibitor (TKI), co-developed by AstraZeneca and Hutchison China MediTech, with commercialization handled by AstraZeneca [1]
和黄医药将在世界肺癌大会和中国临床肿瘤学会年会公布数据